Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study

 
• By Neena Brizmohun

Biosimilar drug makers say that the NOR-SWITCH study on switching from Johnson & Johnson’s infliximab to the Celltrion product supports the concept of biosimilarity and proves that they are subject to the same regulatory standards as originators. Originators, meanwhile, want more evidence that switching works.

Data from a landmark Norwegian study supporting biosimilars switching has fueled the debate over the nascent practice, with the biosimilar industry heralding the study’s significance and originators warning of its weaknesses.

The NOR-SWITCH study results, released on Oct. 18*, showed that physician-led switching from Johnson & Johnson’s originator infliximab, Remicade, to Celltrion’s biosimilar infliximab, Remsima, did not lead to any statistical...

More from Biosimilars

More from Biosimilars & Generics